ArticleHereditas2026
LINC00907 suppresses malignant progression in hepatocellular carcinoma by inhibiting miR-24-3p.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to clarify the role of LINC00907 in hepatocellular carcinoma (HCC) and its underlying molecular mechanisms.
methodsThe research population comprised 117 participants diagnosed with HCC. The expressions of LINC00907 and miR-24-3p in both tissue specimens and cell lines, along with those of EMT markers and the MMP-2 and MMP-9, were measured using RT-qPCR. Cellular proliferation was measured with the CCK-8 assay, while apoptotic rates were determined by flow cytometry. The direct interactions between LINC00907, miR-24-3p, and PDGFRL were validated by dual luciferase reporter and RNA pull-down assays. HCC cells were transfected with constructs specifically modulating LINC00907 and miR-24-3p to investigate the impact of their expression on malignant phenotypic behaviors.
resultsLINC00907 expression was significantly downregulated in HCC, whereas miR-24-3p expression was upregulated. Low LINC00907 expression was linked to significantly worse overall survival, as determined by Kaplan-Meier analysis. The upregulation of LINC00907 led to the suppression of cell proliferation and EMT, while inducing apoptosis and reducing the levels of MMP-2 and MMP-9. LINC00907 was shown to directly target and negatively regulate miR-24-3p. Furthermore, rescue experiments demonstrated that upregulation of miR-24-3p counteracted the tumor-suppressive effects mediated by LINC00907 overexpression in HCC cells.
conclusionLINC00907 exerts tumor-suppressive effects by targeting and negatively regulating miR-24-3p, thereby influencing proliferation, apoptosis, and EMT in HCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.